Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study
- PMID: 18371107
- DOI: 10.1111/j.1365-2141.2008.07144.x
Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study
Abstract
High cure rates are possible in children with localized mature B-cell lymphoma (B NHL) using a variety of chemotherapeutic strategies. To reduce late sequelae, the duration and intensity of chemotherapy has been progressively reduced. The Lymphome Malins de Burkitt (LMB) 89 study reported long-term survival in almost all children with localized resected disease treated with two courses of COPAD (cyclophosphamide, vincristine, prednisolone and doxorubicin). This study was designed to confirm the effectiveness of this approach in a larger number of patients in a multinational co-operative study. The patient cohort was part of an international study (French-American-British LMB 96), which included all disease stages and involved three national groups. Patients in this part of the study had resected stage I or completely resected abdominal stage II disease. Following surgery, two courses of COPAD were given, without intrathecal (IT) chemotherapy. One hundred and thirty-two children were evaluable. Two of 264 (0.9%) courses were associated with grade IV toxicity (one stomatitis and one infection). With a median follow up of 50.5 months, the 4 year event-free survival is 98.3% and overall survival is 99.2%. Children with resected localized B-NHL can be cured with minimal toxicity following two courses of low intensity treatment without IT chemotherapy.
Similar articles
-
[Comparing CHOP, CHOP+HD-MTX,and BFM-90 regimens in the survival rate of children and adolescents with B cell non-Hodgkin's lymphoma].Ai Zheng. 2004 Aug;23(8):933-8. Ai Zheng. 2004. PMID: 15301718 Chinese.
-
[NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphoma in children and adolescents. Part 3: An intermediate term analysis of the B-NHL/B-ALL].Klin Padiatr. 1994 Jul-Aug;206(4):242-52. doi: 10.1055/s-2008-1046610. Klin Padiatr. 1994. PMID: 7967420 Clinical Trial. German.
-
Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol.Br J Cancer. 2000 Apr;82(8):1396-402. doi: 10.1054/bjoc.1999.1083. Br J Cancer. 2000. PMID: 10780517 Free PMC article. Clinical Trial.
-
Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?Transfus Apher Sci. 2007 Aug;37(1):37-41. doi: 10.1016/j.transci.2007.04.004. Epub 2007 Aug 21. Transfus Apher Sci. 2007. PMID: 17714996 Review.
-
Perspectives of the management of childhood lymphoma: experience at Tygerberg Hospital, Western Cape, South Africa.Transfus Apher Sci. 2005 Feb;32(1):27-31. doi: 10.1016/j.transci.2004.10.003. Epub 2005 Jan 22. Transfus Apher Sci. 2005. PMID: 15737871 Review.
Cited by
-
Rituximab-combined anthracycline-free chemotherapy in newly diagnosed paediatric and adolescent patients with non-high-risk aggressive mature B cell lymphoma: protocol for a single-arm, open-label, multicentre, phase II study (the Japan Children's Cancer Group Multicentre Trial, JPLSG B-NHL-20).BMJ Open. 2024 Mar 19;14(3):e080762. doi: 10.1136/bmjopen-2023-080762. BMJ Open. 2024. PMID: 38508620 Free PMC article.
-
Mature B-cell lymphomas in adolescents and young adults.EJHaem. 2023 Sep 8;4(4):912-920. doi: 10.1002/jha2.783. eCollection 2023 Nov. EJHaem. 2023. PMID: 38024628 Free PMC article.
-
Intussusception in a 4-Year-Old Male Due to Burkitt Lymphoma.Case Rep Pediatr. 2023 Mar 27;2023:3535164. doi: 10.1155/2023/3535164. eCollection 2023. Case Rep Pediatr. 2023. PMID: 37020843 Free PMC article.
-
Ultra Short Course Chemotherapy for Early-Stage Non-Hodgkin's Lymphoma in Children.Children (Basel). 2022 Aug 25;9(9):1279. doi: 10.3390/children9091279. Children (Basel). 2022. PMID: 36138588 Free PMC article.
-
Safety analysis of high-dose methotrexate in pediatric non-Hodgkin lymphomas.Pediatr Blood Cancer. 2022 Nov;69(11):e29940. doi: 10.1002/pbc.29940. Epub 2022 Sep 7. Pediatr Blood Cancer. 2022. PMID: 36069680 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical